BioSpace News Archive

BioSTL is a regional organization in St. Louis whose goal is to champion the life sciences in St. Louis and the surrounding region. BioGenerator is the investment arm of BioSTL.

Bristol-Myers Squibb released data from pooled analyses of survival data from four clinical studies in patients with lung cancer treated with Opdivo (nivolumab).

More job cuts are coming to California life science companies. Charles River Labs and Janssen are both making cuts as they reprioritize their businesses, according to Worker Adjustment and Retraining Notifications filed with the state of California.

Across the globe, pharma and biotech companies report deals and pipeline updates, with news from Boehringer Ingelheim, Metrion, Elvie, and more.

Have you thought about what benefits are important to you? Would you request certain benefits from your current employer, or during an interview for a new job?

Cambridge, Mass.-based Editas Medicine and privately-held BlueRock Therapeutics have teamed up and combined their genome editing and cell therapy technologies to discover, develop and manufacture novel engineered cell medicines.

Karolinska Development’s portfolio company Aprea presents results from studies with APR-246 in combination with immune checkpoint blockade.

Dyne Therapeutics closed on a $50 million Series A round. The company was founded, seeded and incubated by Atlas Venture, who led the round, which was joined by Forbion and MPM Capital.

The California-based company also shared positive early data from a beta thalassemia study and announced plans to increase AAV manufacturing.

A recent report by CBRE Research analyzing U.S. life science clusters, found that Houston, Texas is the third-fastest growing life science market from 2014 to 2017. One doesn’t typically think of Texas, let alone Houston, as being a center for the life sciences. Oil, energy and tech, yes, but not life sciences.